Recursion Pharmaceuticals
RXRX
RXRX
332 hedge funds and large institutions have $1.33B invested in Recursion Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 123 increasing their positions, 85 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
12.83% less ownership
Funds ownership: 75.87% → 63.03% (-13%)
16% less capital invested
Capital invested by funds: $1.58B → $1.33B (-$256M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Holders
332
Holding in Top 10
4
Calls
$40.1M
Puts
$29.5M
Top Buyers
| 1 | +$36.7M | |
| 2 | +$35.3M | |
| 3 | +$35M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$18.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
Top Sellers
| 1 | -$63.4M | |
| 2 | -$38.7M | |
| 3 | -$37.6M | |
| 4 |
Morgan Stanley
New York
|
-$8.09M |
| 5 |
BPCE
Bank Pictet & Cie (Europe)
Frankfurt Am Main,
Germany
|
-$7.95M |
